About Amber Bio
Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations. The current paradigm in genetic medicine relies on developing independent therapies for each separate mutation in the patient population. Founded by pioneers in the CRISPR field from leading institutions for gene editing research, the company is developing a first-of-its-kind RNA writing platform capable of editing thousands of diverse mutations across patients with a single product.
Founded in 2022 by Basem Al-Shayeb and Jacob Borrajo.
- Founded
- 2022
- Employees
- 1 to 10
- Total funding
- $26M
Leadership
The top of Amber Bio's org chart, with how many people report into each leader.
Jacob Borrajo
Founder & CEO
5 reports
Patty Biezonski
VP Of Development
2 reports
Max Semler
Chief Business Officer
Kamyab Javanmardi
VP Of Platform
Jobs at Amber Bio
No open positions right now. Explore more companies on TheJobsMap.